Oxford’s vaccine result is a global game changer

Share Canberra's trusted news:

The global pandemic is not over and won’t be for a long time yet – but the light is getting brighter, writes MICHAEL HEAD.

IN the long dark tunnel that has been 2020, November stands out as the month that light appeared. Some might see it as a bright light, others as a faint light – but it is unmistakably a light.

Senior global health research fellow at University of Southampton, Michael Head.

On November 9, Pfizer announced the interim results of its candidate vaccine, showing it to be “more than 90 per cent effective” in preventing symptomatic COVID-19 in late-stage human trials. The news was greeted with joy.

A couple of days later, the Russian Direct Investment Fund announced that the candidate vaccine they are funding – dubbed Sputnik V – showed 92 per cent efficacy in late-stage trials. Not to be outdone, Moderna then announced that its candidate vaccine showed 94.5 per cent efficacy.

The latest COVID-19 vaccine announcement comes from Oxford University. And, as with all of the above announcements, it came via press release. Its vaccine candidate, developed in partnership with AstraZeneca, showed an overall effectiveness of 70.4 per cent.

In case that sounds disappointing, bear in mind that these are interim results and the figures might change. Also, the Oxford vaccine was given to one group of volunteers as two standard doses, which showed 62 per cent effectiveness, and another group of volunteers as a smaller dose followed by a standard second dose. This raised effectiveness to 90 per cent.

It’s not immediately clear why this is the case. Prof Andrew Pollard, one of the lead researchers on the project, described the results as “intriguing”. He also highlighted that the use of lower doses means that there would be more vaccine doses available.

There were no cases of severe COVID-19 in those who received the vaccine. And it seems to generate a protective immune response in older people. Although we’ll have to wait for the final breakdown of results to get clarification on that.

Effectiveness is not the only measure

Despite the Oxford vaccine having lower overall effectiveness than the Pfizer or Moderna vaccines – at least at this interim stage – there are other success factors to consider. Safety is one, and the Oxford vaccine is so far reported to have a good safety record with no serious side-effects.

Another crucial factor is storage. The Oxford vaccine can be stored in a domestic fridge. The need for sustained freezing across the whole vaccine journey from factory to clinic at ultra-low temperatures – as seen with the Pfizer vaccine – may be a problem for many countries, but especially poorer countries.

The Oxford vaccine, based on a viral vector, is also cheaper (around $US4) than Pfizer and Moderna’s mRNA vaccines – around $US20 and $US33, respectively. AstraZeneca has made a “no profit pledge”.

Equitable distribution

As I have previously discussed, equitable distribution of new vaccines is vital, especially for low- and middle-income countries who don’t have the profile or purchasing power of wealthier countries. GAVI – a global health partnership that aims to increase access to immunisation in poor countries – has worked for years to address this very point. It set up the COVAX initiative in 2020, which has access to 700 million doses of covid vaccine if clinical trials are successful.

Oxford and AstraZeneca have previously made their own commitments to provide a billion doses of their vaccine for low- and middle-income countries, with a commitment to provide 400 million doses before the end of 2020. Certainly, AstraZeneca has committed to provide more doses to countries outside of Europe and the US than any of its nearest competitors.

An excellent start

These commitments will clearly not be enough for immediate global coverage, but it is an excellent start. Around 9 per cent of the world’s population live in extreme poverty, and the health systems around them are fragile. With promises for equitable vaccine distribution, there is hope that the poorer populations around the world will not be forgotten. The global health community must keep its focus on this area.

What does this announcement mean for the world? Potentially a huge amount. But remember that the trials are not yet complete and, at the time of writing, the regulators have yet to approve any of the new vaccine candidates. Even when those hurdles are cleared, we still need to vaccinate the world, which requires successfully navigating the complex obstacles of distance, terrain, politics, cold-chain logistics and human behaviour.

The global pandemic is not over and won’t be for a long time yet – but the light is getting brighter.

Michael Head is a senior research fellow in global health at the University of Southampton. This article was originally published on The Conversation

Who Can You Trust?

In a world beleaguered by spin and confused messages, there's never been more need for diverse, trustworthy, independent journalism in Canberra.

Who can you trust? Well, for more than 25 years, "CityNews" has proudly been an independent, free, family-owned news magazine, serving the national capital with quality, integrity and authority. Through our weekly magazine and daily through our digital platforms, we constantly and reliably deliver high-quality and diverse opinion, news, arts, socials and lifestyle columns.

If you trust our work online and believe in the power of independent voices, I encourage you to make a small contribution.

Every dollar of support will be invested back into our journalism so we can continue to provide a valuably different view of what's happening around you and keep citynews.com.au free.

Click here to make your donation and you will be supporting the future of journalism and media diversity in the ACT.

Thank you,

Ian Meikle, editor

Previous articleLong, chilly night pays off for top photo winner
Next articleMore than 100 people set to fly in from Singapore

Leave a Reply